National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
AI10721-01
米国
引用
ジャーナル: Nat Commun / 年: 2026 タイトル: Neutralizing human monoclonal antibodies to poliovirus map to the receptor binding site. 著者: Benjamin T Waddey / Andrew J Charnesky / Julia E Faust / Nadia M DiNunno / Rama Devudu Puligedda / Sung Hyun Cho / Carol M Bator / Steven D Dong / Kutub Mahmood / Konstantin M Chumakov / ...著者: Benjamin T Waddey / Andrew J Charnesky / Julia E Faust / Nadia M DiNunno / Rama Devudu Puligedda / Sung Hyun Cho / Carol M Bator / Steven D Dong / Kutub Mahmood / Konstantin M Chumakov / Scott K Dessain / Susan L Hafenstein / 要旨: Poliovirus remains a serious threat to human health. Complete eradication of wild-type poliovirus has not yet succeeded, making the development of successful antivirals critical. Microneutralization ...Poliovirus remains a serious threat to human health. Complete eradication of wild-type poliovirus has not yet succeeded, making the development of successful antivirals critical. Microneutralization assays against all three poliovirus serotypes identified a panel of human monoclonal IgGs, which are either serotype-specific or cross-neutralizing. Here, through cryoEM single particle analysis, we solved high resolution structures of four distinct poliovirus-FAb complexes. These antibodies bind to capsids at the circular depression (canyon) surrounding the icosahedral five-fold symmetry axis, which is also the binding site of the poliovirus receptor (PVR). Analysis of these structures confirms overlap of FAb contacts on the viral capsid with those of PVR. For three of the FAbs, the capsid residues are identified that dictate serotype-specific recognition. Contacts for the cross-neutralizing mAb 10D2 are located deep in the capsid canyon. These structural analyses indicate that antibody competition with the receptor likely leads to neutralization of virus particles and inhibition of poliovirus entry into host cells. Thus, the human IgGs studied here may facilitate development of therapeutics for the ongoing efforts in global eradication of poliovirus.
履歴
登録
2025年4月24日
登録サイト: RCSB / 処理サイト: RCSB
改定 1.0
2025年12月17日
Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: EM metadata / Data content type: EM metadata / Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: FSC / Data content type: FSC / Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: Half map / Part number: 1 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: Half map / Part number: 2 / Data content type: Half map / Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: Image / Data content type: Image / Provider: repository / タイプ: Initial release
改定 1.0
2025年12月17日
Data content type: Primary map / Data content type: Primary map / Provider: repository / タイプ: Initial release
Data content type: EM metadata / Data content type: EM metadata / EM metadata / Group: Database references / Experimental summary / Data content type: EM metadata / EM metadata / EM metadata / カテゴリ: citation / citation_author / em_admin Data content type: EM metadata / EM metadata ...EM metadata / EM metadata / EM metadata / EM metadata / EM metadata Item: _citation.pdbx_database_id_DOI / _citation.pdbx_database_id_PubMed ..._citation.pdbx_database_id_DOI / _citation.pdbx_database_id_PubMed / _citation.title / _citation.year / _em_admin.last_update